Department of Head and Neck Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
Department of Etiology and Carcinogenesis, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
Biochem Genet. 2022 Dec;60(6):2313-2326. doi: 10.1007/s10528-022-10218-3. Epub 2022 Mar 29.
To investigate the expression and mechanism of LSC27A6 in papillary thyroid cancer (PTC). We analyzed the differential expression of SLC27A6 in PTC tissues and normal tissues based on the TCGA database and validated it using immunohistochemistry. Wilcoxon rank sum, chi-square test, or Fisher exact exam were used to analyze the relationship between the expression of SLC27A6 and clinicopathological information. Samples were divided into two groups according to whether BRAF was mutated or not, and Wilcoxon rank sum was used to determine whether the expression of SLC27A6 was related to BRAF mutation. The effects of SLC27A6 on the proliferation, migration, and apoptosis of PTC cells were detected by cell counting kit-8 (CCK8), colony formation assay, transwell assay, and flow cytometry. Spearman correlation analysis was used to evaluate the relationship between SLC27A6 and c-MYC. Protein expression was detected by Western blot. The expression of SLC27A6 was higher in PTC and positively correlated with N stage. SLC27A6 expression was higher in samples with BRAF mutations. Down-regulation of SLC27A6 inhibited cell proliferation, migration, and invasion and induced apoptosis. Spearman correlation analysis showed that SLC27A6 was positively correlated with c-MYC. Knockdown of SLC27A6 inhibited c-MYC expression. Our results suggest that SLC27A6 is overexpressed in PTC tissues and affects the progression of PTC by regulating c-MYC.
为了研究 LSC27A6 在甲状腺乳头状癌（PTC）中的表达和机制。我们基于 TCGA 数据库分析了 SLC27A6 在 PTC 组织和正常组织中的差异表达，并通过免疫组织化学进行了验证。Wilcoxon 秩和检验、卡方检验或 Fisher 确切检验用于分析 SLC27A6 的表达与临床病理信息之间的关系。根据是否存在 BRAF 突变将样本分为两组，采用 Wilcoxon 秩和检验确定 SLC27A6 的表达是否与 BRAF 突变有关。通过细胞计数试剂盒-8（CCK8）、集落形成实验、Transwell 实验和流式细胞术检测 SLC27A6 对 PTC 细胞增殖、迁移和凋亡的影响。Spearman 相关分析用于评估 SLC27A6 与 c-MYC 之间的关系。通过 Western blot 检测蛋白表达。SLC27A6 在 PTC 中表达较高，与 N 分期呈正相关。SLC27A6 在存在 BRAF 突变的样本中表达较高。下调 SLC27A6 抑制细胞增殖、迁移和侵袭并诱导凋亡。Spearman 相关分析表明 SLC27A6 与 c-MYC 呈正相关。敲低 SLC27A6 抑制 c-MYC 表达。我们的结果表明，SLC27A6 在 PTC 组织中过度表达，并通过调节 c-MYC 影响 PTC 的进展。
